You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貴州百靈(002424.SZ):通過技術轉讓獲得“治療呼吸道病毒感染中藥1類新藥(暫定名BD-77)”項目
格隆匯 01-13 18:36

格隆匯1月13日丨貴州百靈(002424.SZ)公佈,公司(“甲方”)於近日與中國中醫科學院中藥研究所(“乙方”)簽訂《技術轉讓合同》。乙方自願將其擁有的“治療呼吸道病毒感染中藥1類新藥(暫定名BD-77)”相關技術轉讓給甲方,甲方自願受讓並支付相應的轉讓費,技術轉讓費為2000萬元。

該項目系從《中國藥典》收載的單一藥材中提取純化獲得純度超過95%的單體化合物及其製劑,按《藥品註冊管理辦法》中藥註冊分類1.2類中藥新藥技術要求進行開發,具有獨立自主知識產權。目前已完成創新中藥成藥性評價階段的全部研究,突破了創新藥臨牀前研發中各環節的關鍵技術,有望成為目前全球在研抗新冠感染藥物中極具競爭力的藥品之一。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account